Frédéric Pouliot

10.5k total citations · 5 hit papers
196 papers, 4.5k citations indexed

About

Frédéric Pouliot is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Frédéric Pouliot has authored 196 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Pulmonary and Respiratory Medicine, 64 papers in Molecular Biology and 54 papers in Oncology. Recurrent topics in Frédéric Pouliot's work include Prostate Cancer Treatment and Research (79 papers), Renal cell carcinoma treatment (75 papers) and Renal and related cancers (40 papers). Frédéric Pouliot is often cited by papers focused on Prostate Cancer Treatment and Research (79 papers), Renal cell carcinoma treatment (75 papers) and Renal and related cancers (40 papers). Frédéric Pouliot collaborates with scholars based in Canada, United States and United Kingdom. Frédéric Pouliot's co-authors include Stéphane Bolduc, Cassandra Ringuette Goulet, Stéphane Chabaud, Geneviève Bernard, Claude Labrie, Rustem Gafanov, Michael B. Atkins, Audrey Champagne, Arie S. Belldegrun and Sarah Tremblay and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Frédéric Pouliot

186 papers receiving 4.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

2020 498 citations Denis Soulières, Rustem Gafanov et al. profile →
Cancer-associated fibroblasts induce epithelial–mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling

2019 244 citations Cassandra Ringuette Goulet, Audrey Champagne et al. profile →
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY)

2021 244 citations Michael A. Gorin, Steven P. Rowe et al. profile →
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

2021 237 citations Michael J. Morris, Steven P. Rowe et al. Clinical Cancer Research profile →
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

2021 183 citations David F. McDermott, Jae‐Lyun Lee et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frédéric Pouliot Canada	31	2.8k	1.8k	1.4k	1.1k	647	196	4.5k
Mauro Papotti Italy	37	2.7k 1.0×	1.3k 0.7×	1.7k 1.2×	1.1k 1.0×	475 0.7×	96	4.6k
Sylvie Lantuéjoul France	45	3.7k 1.3×	2.1k 1.2×	3.2k 2.2×	1.2k 1.2×	662 1.0×	154	6.9k
Hyo Sup Shim South Korea	37	3.1k 1.1×	1.5k 0.8×	2.4k 1.7×	1.1k 1.1×	429 0.7×	164	5.1k
Begoña Mellado Spain	36	2.2k 0.8×	2.0k 1.1×	1.9k 1.3×	1.1k 1.1×	947 1.5×	180	4.7k
Andres Jan Schrader Germany	34	2.0k 0.7×	1.1k 0.6×	1.2k 0.8×	844 0.8×	707 1.1×	162	3.8k
Ulrik Lassen Denmark	36	1.6k 0.6×	1.7k 0.9×	2.2k 1.5×	1.0k 1.0×	644 1.0×	253	4.9k
Zohar Dotan Israel	23	2.6k 0.9×	2.3k 1.2×	1.0k 0.7×	899 0.9×	1.0k 1.6×	128	5.4k
Roberto Iacovelli Italy	34	2.6k 0.9×	1.5k 0.8×	2.1k 1.5×	1.2k 1.2×	712 1.1×	224	4.6k
Matthew M. Cooney United States	24	3.6k 1.3×	1.0k 0.6×	1.8k 1.3×	1.1k 1.1×	367 0.6×	86	5.2k
Vincenza Conteduca Italy	38	2.1k 0.7×	987 0.5×	1.2k 0.8×	1.1k 1.1×	537 0.8×	151	3.8k

Countries citing papers authored by Frédéric Pouliot

Since Specialization

Citations

This map shows the geographic impact of Frédéric Pouliot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Pouliot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Pouliot more than expected).

Fields of papers citing papers by Frédéric Pouliot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Pouliot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Pouliot. The network helps show where Frédéric Pouliot may publish in the future.

Co-authorship network of co-authors of Frédéric Pouliot

This figure shows the co-authorship network connecting the top 25 collaborators of Frédéric Pouliot. A scholar is included among the top collaborators of Frédéric Pouliot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frédéric Pouliot. Frédéric Pouliot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

So, Alan, Kim Chi, Brita Danielson, et al.. (2025). 2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castrationsensitive prostate cancer (Update). Canadian Urological Association Journal. 19(5). E142–52.

Ghosh, Sunita, Lori Wood, C. Kollmannsberger, et al.. (2025). Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients. Cancers. 17(3). 522–522. 2 indexed citations

Yu, Evan Y., Vivek Narayan, Giuseppe Esposito, et al.. (2024). 1604P PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW. Annals of Oncology. 35. S967–S968. 1 indexed citations

Rouleau, Mélanie, et al.. (2023). Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy. The Prostate. 83(7). 670–677. 1 indexed citations

Tremblay, Samuel, Andrew Weickhardt, Ian D. Davis, et al.. (2023). Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial. Cancer Imaging. 23(1). 57–57. 1 indexed citations

Ghosh, Sunita, Antonio Finelli, Lori Wood, et al.. (2023). Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System. JCO Global Oncology. 9(9). e2300271–e2300271. 1 indexed citations

Berthiaume, Line, Mario Harvey, Bertrand Neveu, et al.. (2023). Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer. Molecular Oncology. 17(10). 2109–2125. 8 indexed citations

Pellerin, Ève, et al.. (2022). Bisphenols A and S Alter the Bioenergetics and Behaviours of Normal Urothelial and Bladder Cancer Cells. Cancers. 14(16). 4011–4011. 8 indexed citations

Morris, Michael J., Steven P. Rowe, Michael A. Gorin, et al.. (2021). Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clinical Cancer Research. 27(13). 3674–3682. 237 indexed citations breakdown →

10.

McDermott, David F., Jae‐Lyun Lee, Marek Ziobro, et al.. (2021). Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1029–1039. 183 indexed citations breakdown →

11.

Pellerin, Ève, Stéphane Chabaud, Frédéric Pouliot, Martin Pelletier, & Stéphane Bolduc. (2021). Bisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression. Cancers. 13(21). 5461–5461. 15 indexed citations

12.

Shiff, Benjamin, Rodney H. Breau, Ranjeeta Mallick, et al.. (2021). Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. Urologic Oncology Seminars and Original Investigations. 39(12). 836.e19–836.e27. 13 indexed citations

13.

Kushnir, Igal, Naveen S. Basappa, Sunita Ghosh, et al.. (2021). Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical Genitourinary Cancer. 19(6). 521–530. 12 indexed citations

14.

Goulet, Cassandra Ringuette, Hélène Hovington, Véronique Lefebvre, et al.. (2020). GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome. Prostate Cancer and Prostatic Diseases. 23(3). 441–448. 44 indexed citations

15.

Joncas, France‐Hélène, Fabrice Lucien, Mélanie Rouleau, et al.. (2019). Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients. The Prostate. 79(15). 1767–1776. 60 indexed citations

16.

Goulet, Cassandra Ringuette, Geneviève Bernard, Sarah Tremblay, et al.. (2018). Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGFβ Signaling. Molecular Cancer Research. 16(7). 1196–1204. 256 indexed citations

17.

Toren, Paul, Keyue Ding, France‐Hélène Joncas, et al.. (2018). Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. Clinical Cancer Research. 24(21). 5305–5312. 15 indexed citations

18.

Beauregard, Jean‐Mathieu, et al.. (2017). Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. European Urology Focus. 3(6). 639–642. 13 indexed citations

19.

Escamilla, Jemima, Shiruyeh Schokrpur, Saul J. Priceman, et al.. (2015). CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. Cancer Research. 75(6). 950–962. 149 indexed citations

20.

Lacombe, Louis, Vincent Fradet, Éric Lévesque, et al.. (2015). Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non–Muscle-Invasive Bladder Cancer: A Gene–Smoking Interaction. Cancer Prevention Research. 9(2). 189–195. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact